SARASOTA, Fla. and MONTERREY, Mexico, Oct.
14, 2021 /PRNewswire/ -- INVO Bioscience, Inc.
(NASDAQ: INVO), a medical device company focused on commercializing
the world's only in vivo culture system (IVC), INVOcell®, today
announced November 1, 2021 as the
grand opening date for the Company's INVO Center joint venture,
based in Monterrey, Mexico. The
new center, named "Positib Fertility, an INVO Center," will focus
on patients in need of advanced fertility care utilizing the
efficient, effective, and affordable INVOcell solution. This
becomes the first INVO Center in Mexico and follows the recent openings of INVO
Centers in Birmingham, Alabama and
Atlanta, Georgia.
Positib Fertility, an INVO Center, is a partnership between INVO
Bioscience and experienced reproductive specialist Dr. Francisco Arredondo, MD., MPH and Dr.
Ramiro Ramirez Gutierrez, MD. Dr.
Arredondo was an early adopter of the INVOcell solution as he began
offering IVC via the INVOcell to his patients at fertility clinics
in San Antonio and Austin in 2016. In 2017, due to the success in
expanding the accessibility of infertility treatment to patients
utilizing INVOcell, he decided to open a center where he would
exclusively offer the INVOcell solution in McAllen, Texas. Dr. Arredondo successfully
sold his U.S.-based fertility clinics in 2019 and is now focused on
bringing the INVOcell solution to Mexico.
Dr. Arredondo commented, "I am incredibly excited to announce
the grand opening of the first INVO Center in Mexico, 'Positib Fertility,' focused on the
providing patients with an effective and affordable infertility
solution. As an early adopter of the truly remarkable INVOcell
technology while practicing in the United
States, I was able witness the joy that can be brought to so
many families struggling with fertility. I look forward to bringing
that same joy to the people of Monterrey and the surrounding areas by the
opening of this first-of-its-kind clinic in Mexico."
Steve Shum, CEO of INVO
Bioscience, commented, "This is yet another milestone in the
history of the Company and the INVOcell solution as we announce the
grand opening of our first INVO Center in Mexico. Drs. Arredondo and Ramirez are leaders
in the fertility industry, and more importantly, are highly
passionate and dedicated to helping the families in Mexico who struggle with infertility. This is
an exciting time for the industry as we take yet another
significant step forward to advance our core mission of improving
access to advanced fertility services for the many patients around
the world through the use of the INVOcell solution."
Ramiro Ramirez, MD, of Positib
Fertility, added, "For too long, advanced fertility services have
been largely unattainable to a large segment of the global
population due to industry capacity and cost. I look forward to the
opening of Positib Fertility leveraging the INVOcell technology
which solves these two critical challenges helping to achieve the
goal of democratizing fertility services."
Positib Fertility, an
INVO Center, is located at
Bosques del Valle #112, Col. Bosques del Valle, San Pedro Garza
García, NL 66250, Mexico.
About INVOcell
The INVOcell procedure is the first in-vivo culture (IVC) system
in the world used for the incubation of eggs and sperm during
fertilization and early embryo development within the body, as an
alternative to conventional In Vitro Fertilization (IVF) and
Intrauterine Insemination (IUI). Through its in vivo approach,
INVOcell offers patients a more natural and intimate experience
with comparable results at a lower cost.
About INVO Bioscience
We are a medical device company focused on creating simplified,
affordable treatments for patients diagnosed with infertility. Our
solution, the INVO® Procedure, is a revolutionary in vivo method of
vaginal incubation that offers patients a more natural and intimate
experience. Our lead product, the INVOcell®, is a patented medical
device used in infertility treatment and is considered an Assisted
Reproductive Technology (ART). The INVOcell® is the first
Intravaginal Culture (IVC) system in the world used for the natural
in vivo incubation of eggs and sperm during fertilization and early
embryo development, as an alternative to traditional In Vitro
Fertilization (IVF) and Intrauterine Insemination (IUI). Our
mission is to increase access to care and expand fertility
treatment across the globe with a goal to lower the cost of care
and increase the availability of care. For more information, please
visit http://invobioscience.com/
Safe Harbor Statement
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
The Company invokes the protections of the Private Securities
Litigation Reform Act of 1995. All statements regarding our
expected future financial position, results of operations, cash
flows, financing plans, business strategies, products and services,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond our control, which may
cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from
those in the forward-looking statements include those set forth in
our filings at www.sec.gov. We are under no obligation to (and
expressly disclaim any such obligation to) update or alter our
forward-looking statements, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invo-bioscience-announces-grand-opening-of-positib-fertility-an-invo-center-in-monterrey-mexico-on-november-1-2021-301400026.html
SOURCE INVO Bioscience, Inc.